^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CB-010

    i
    Other names: CB-010
    Company:
    Caribou Biosci
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    4ms
    CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (clinicaltrials.gov)
    P1, N=72, Recruiting, Caribou Biosciences, Inc.
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CB-010
    11ms
    Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. (PubMed, Cytotherapy)
    Genomic PD-1 checkpoint disruption in the context of allogeneic CAR-T cell therapy may provide a compelling option for treating B lymphoid malignancies.
    Journal • CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    CB-010
    over1year
    A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study) (ASH 2022)
    After serially receiving lymphodepletion therapy with cyclophosphamide (60mg/kg/day for 2 days) and fludarabine (25mg/m2/day for 5 days), pts receive a single dose infusion of CB-010 and are followed for safety and efficacy. Dose escalation of CB-010 is ongoing, and patients are being enrolled in cohort 2 to receive a single dose of 80 million CAR-T cells. The ANTLER Phase 1 trial is registered on clinicaltrials.gov (NCT04637763).
    Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    cyclophosphamide • fludarabine IV • CB-010